Abstracts tagged "fibromyalgia"

Abstract Number: LB03 • ACR Convergence 2025
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
Leslie Crofford¹, Dana Dailey², Barbara Van Gorp², Carol Vance², Andrew Post³, Ruth Chimenti², Ezgi Yarasir², Elizabeth Johnson¹, Kari Vance², Bridget Zimmerman², Fangfang Jiang², David-Erick Lafontant², Maxine Koepp², Dixie Ecklund², Emine Bayman² and Kathleen Sluka², ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²University of Iowa, Iowa City, Iowa, ³Grand Valley State University, Grand Rapids, Michigan
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain that is often exacerbated by movement. FM is associated with enhanced central pain transmission, while transcutaneous…
Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Felipe Massó¹, Laura Aline Martinez-Martinez², Luis M Amezcua-Guerra³, Francisco Mercado⁴, Angélica Almanza⁵ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ⁴Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, ⁵Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
Abstract Number: 1231 • ACR Convergence 2025
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Gregory Sullivan¹, Errol Gould², Mary Kelley¹, Jean Engels¹ and Seth Lederman³, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceutical, Inc., Henderson, NV, ³Tonix Pharmaceuticals, Inc., Austin, TX
Background/Purpose: FDA-approved treatments for fibromyalgia (FM) have historically been limited by intolerable side effects that often lead to poor adherence. TNX-102 SL, a sublingual formulation…
Abstract Number: 1228 • ACR Convergence 2025
Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Brennan Spiegel¹, Jeffrey Curtis², Yashar Eshraghi³, Maged Guirguis³, Beth Darnall⁴, Christine Rini⁵, Emily Holladay⁶, Mehra Muskaan¹, So Yung Choi¹ and Samuel Eberlein¹, ¹Cedars Sinai, Los Angeles, CA, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³University of Queensland Ochsner Medical School, New Orleans, LA, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵Northwestern University, Chicago, IL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evidence-based behavioral treatments for chronic pain are largely inaccessible, particularly to rural patients. This decentralized randomized controlled trial compared the effectiveness of two digital,…
Abstract Number: 2437 • ACR Convergence 2025
Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Aaron Smith¹, Thuyvan Phan², Leah Luizza³, Anthony Trujillo³, Becki Cleveland¹, Shruti Saxena Beem⁴, Tessa Englund⁵, Claire Timon⁴ and Saira Sheikh⁵, ¹University of North Carolina, Chapel Hill, NC, ²UNC Health, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, ⁴University of North Carolina at Chapel Hill, Chapel Hill, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-system autoimmune disease with heterogenous presentation. Most patients with SLE report fatigue or brain fog, which often…
Abstract Number: 1226 • ACR Convergence 2025
Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome
Daniella Schocken¹, Mark Connelly², Sabrina Gmuca³, Andrea Ramirez⁴, Mary Ellen Riordan⁵, Tracy Ting⁶, Susmita Kashikar-Zuck⁷ and Jennifer Weiss⁸, ¹Children's Mercy Kansas City, Tampa, FL, ²Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, MO, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Baylor College of Medicine, Houston, TX, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: Diagnosing juvenile fibromyalgia (JFM) in youth with chronic musculoskeletal (MSK) pain is challenging in the absence of a validated diagnostic tool. The Pain and…
Abstract Number: 2378 • ACR Convergence 2025
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Alvaro Oyarce-Calderón¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Samira Garcia-Hirsh⁴, Zoila Rodríguez-Bellido⁵, Cesar Pastor-Asurza⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
Abstract Number: 1225 • ACR Convergence 2025
Association between Anxiety and Tender Swollen Joint Difference in Patients with Rheumatoid Arthritis
Clarice Lin¹, Burcu Aydemir², Jing Song³, Lutfiyya muhammad², Clifton Bingham⁴, Tuhina Neogi⁵, Wendy Marder⁶, Marcy Bolster⁷, Daniel Clauw⁸, Dorothy Dunlop⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Worthington, MN, ⁴Johns Hopkins University, Baltimore, MD, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Michigan, Ann Arbor, MI, ⁷Massachusetts General Hospital, Concord, MA, ⁸Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁹Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Some patients with rheumatoid arthritis (RA) have pain, despite normalization of inflammatory markers and reduced swollen joint counts. Among these patients, the number of…
Abstract Number: 2189 • ACR Convergence 2025
Physician Practices and Perspectives in the Diagnosis and Management of Fibromyalgia: A US Chart Review Study
Daniel Clauw¹, Parul Houston², Zhao Yang², Todd Grinnell² and Lesley Arnold³, ¹Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ²Axsome Therapeutics, Inc, New York, NY, ³University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing, which impairs daily function and quality of life. Current understanding…
Abstract Number: 1224 • ACR Convergence 2025
Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients
Chukwuemelie Okeke¹, Queeneth Edwards², Ufuoma Mamoh³, Justin Riley Lam⁴ and Chekwubejah Uwakwe⁵, ¹Maimonides Medical Center, Brooklyn, NY, ²Department of Epidemiology and Biostatistics, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, ³Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁴Jefferson Einstein Hospital, Philadelphia, PA, ⁵Nnamdi Azikiwe University Teaching Hospital, Nigeria, Nnewi, Anambra, Nigeria
Background/Purpose: Fibromyalgia (FM) is a chronic, debilitating condition characterized by widespread pain, fatigue, and cognitive disturbances. Despite the availability of FDA-approved treatments, real-world comparative effectiveness…
Abstract Number: 2098 • ACR Convergence 2025
Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Natalie Keller¹, Bryant England², Katherine Wysham³, Mercedes Quinones⁴, Marianna Olave⁵, Sarah Wetzel⁶, Hannah Brubeck⁷, Rachel Gillcrist⁶, Criswell Lavery⁸, Bibiana Ateh⁹, Bridget Kramer², Kimberly Hayes⁶, Rui Xiao⁸, Kaitian Jin⁸, Alexis Ogdie⁸, Daniel K. White¹⁰, Tuhina Neogi¹¹, Carla Scanzello¹² and Joshua Baker⁸, ¹University of Oklahoma, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Howard University Hospital and Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, ⁵Brown University, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁷VA Puget Sound Health Care System, Seattle, WA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Washington VA Medical Center, Washington, District of Columbia, ¹⁰University of Delaware, Newark, DE, ¹¹Boston University School of Medicine, Boston, MA, ¹²University of Pennsylvania, Philadelphia
Background/Purpose: Intra-articular (IA) corticosteroid injections are commonly utilized for pain management in knee osteoarthritis (KOA). However, clinical characteristics associated with a greater benefit from corticosteroid…
Abstract Number: 1221 • ACR Convergence 2025
Oxytocin pathway gene BST1 polymorphism rs4273468 genotype GG is negatively associated with Fibromyalgia
Zeeshan Ahmed¹, Koshy Nithin Thomas², Shivika Guleria³, Amita Aggarwal⁴ and Able Lawrence³, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Oxytocin, also known as love hormone, is important in contextual memory. Oxytocin secreting parvocellular neurons suppress pain through projections to brain and spinal cord…
Abstract Number: 1435 • ACR Convergence 2025
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Denis Poddubnyy¹, Victoria Navarro-Compan², Neil Basu³, Mohammad Naffaa⁴, Tianming Gao⁵, Christopher Saffore⁶, Jamie Urbanik⁷, Bhumik Parikh⁸, Peter Taylor⁹ and Philip J. Mease¹⁰, ¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, ⁵AbbVie, North Chicago, IL, ⁶AbbVie Inc., waukegan, IL, ⁷AbbVie, Grayslake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹University of Oxford, Oxford, United Kingdom, ¹⁰Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
Abstract Number: 1014 • ACR Convergence 2025
Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank
Sung-A Kim, Gary Macfarlane and Marcus Beasley, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: The diagnosis of fibromyalgia (FM) is challenging due to its reliance on patient-reported symptoms, the absence of definitive biomarkers, and numerous overlapping comorbidities. Discrepancies…
Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Gilad Halpert¹, Yair Dankner², Eri Govrin¹, Abdulla Watad³, Omer Gendelman¹, Shlomo Segev¹, Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Shenkar College of Engineering and Design, Ramar Gan, Israel, ³Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…

1
2
3
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].